Charles Schwab
ZSAN

Charles Schwab’s Zosano Pharma Corporation ZSAN Stock Holding History

Charles Schwab’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,212
Closed -$41K – 3576
2021
Q2 		$41K Hold
1,212
– – ﹤0.01% 3396
2021
Q1 		$53K Buy
+1,212
New +$50.8K ﹤0.01% 3433

Other funds holding ZSAN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Charles Schwab's ZSAN Position: Q3 2021 in Review

Charles Schwab sold out of Zosano Pharma Corporation (ZSAN) in Q3 2021, closing a stake of 1,212 shares — an estimated $41K sold.

Charles Schwab first reported a position in ZSAN in Q1 2021 and held it in 2 quarters. The position peaked at $53K in Q1 2021. 32 funds tracked by Wall St. Rank hold ZSAN as of Q3 2021.

  • Charles Schwab reported no remaining Zosano Pharma Corporation position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 1,212 Zosano Pharma Corporation shares in Q3 2021, an estimated $41K.
  • Charles Schwab first reported a position in Zosano Pharma Corporation in Q1 2021 and held it in 2 quarters.
  • Charles Schwab's Zosano Pharma Corporation position peaked at $53K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.